Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma.
W Croft, H Pearce, S Margielewska-Davies, L Lim… - 2023 - westmid.openrepository.com
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
[PDF][PDF] Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - scholar.archive.org
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma.
W Croft, H Pearce, S Margielewska-Davies, L Lim… - Elife, 2023 - europepmc.org
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
[HTML][HTML] Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - eLife, 2023 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma.
W Croft, H Pearce, S Margielewska-Davies, L Lim… - eLife, 2023 - search.ebscohost.com
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - bioRxiv, 2023 - biorxiv.org
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - eLife - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
[PDF][PDF] Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - research.birmingham.ac.uk
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
W Croft, H Pearce, S Margielewska-Davies, L Lim… - eLife, 2023 - search.proquest.com
Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …